A novel two step blood test for the early diagnosis of Alzheimer disease – 2015 – MINECO
AD-2step aims at validating a diagnostic test for Alzheimer’s disease (AD) based on several previously identified markers in the blood. This blood-based test will be easily adaptable to medical laboratories with standard analysis platforms, allowing an inexpensive diagnosis. It represents an important business opportunity, and a key scientific breakthrough that would allow for the first time the differential diagnosis of dementia.
The development of strategic partnerships and alliances represents a key challenge for Biocross. The development of strategic partnerships and alliances represents a key challenge for Biocross, and is of the utmost importance given the continuous changes occuring within the field of neurology.
Development of a diagnostic system for Alzheimer’s disease – 2013 – Innocash (Genoma España)
The main objective is to develop a product that enables diagnosis of Alzheimer’s disease from blood samples with a sensitivity and specificity higher than that of any currently available method (>85%).
Design and construction of a system for diagnosing Alzheimer’s disease based on laser raman spectroscopy – 2012 – INNPACTO (MINECO).
Innovative solutions to accelerate the identification and development of drugs for diseases of the nervous system – 2011 – CENIT (CDTI)
To develop new experimental and technological approaches to identify candidate compounds for future therapies for nervous system diseases.
Development of a prototype of a high resolution diagnostic test blood for Alzheimer’s disease – 2010 – CDTI
The main objective of the project is to develop a prototype of a diagnostic blood test that will enable clinical diagnosis of Alzheimer’s disease with greater accuracy than currently available
Investigation of a process for early detection of Alzheimer’s disease – 2009 – IMADE
The aim of this project is to develop and commercialize new products for the non-invasive diagnosis of Alzheimer’s disease. These will allow diagnosis of this disease at much earlier stages than currently possible, with greater reliability and less disruption to patients
If you have any questions or comments, we will be pleased to attend you
If you have any questions or comments,
we will be pleased to attend you